Genmab's 15-minute chart: MACD Death Cross and KDJ Death Cross observed.

Based on the 15-minute chart for Genmab, the MACD indicator has recently crossed below its signal line, while the KDJ indicator has also reached a point of convergence with the 20-day moving average, both occurring at 09:45 on October 20, 2025. This technical configuration suggests that the stock price has the potential to continue trending downwards, with a shift in momentum towards the downside. Furthermore, there is a possibility that the stock price may experience a further decrease in value.

Genmab A/S (CSE:GMAB) shares fell more than 3% on Monday after new data from Johnson & Johnson’s amivantamab suggested the drug could rival Genmab and Merus N.V.’s petosemtamab in head and neck cancer treatment. The data, released as part of Johnson & Johnson’s Phase 1 OrigAMI-4 trial, showed amivantamab achieved an overall response rate of 44.7%, a duration of response of 7.2 months, and a median progression-free survival of 6.8 months in patients with second-line or later recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, as reported by Investing.com.

Petosemtamab, Genmab’s drug, reported a 36% response rate, 6.2-month duration of response, and 4.9-month median progression-free survival in its corresponding study. However, Truist Securities noted that the OrigAMI-4 study excluded HPV-positive patients, while about 20% of those in the petosemtamab study were HPV-positive, a group that typically shows limited response to EGFR-targeted therapies. When adjusted for similar patient populations, both therapies demonstrated comparable efficacy.

The new data prompted Janssen, the pharmaceutical arm of Johnson & Johnson, to announce plans to initiate the Phase 3 OrigAMI-5 trial, which will test a combination of amivantamab, pembrolizumab, and carboplatin in first-line HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma. Truist described the new amivantamab data as a potential competitive challenge to petosemtamab but maintained its “buy” rating on Genmab with a price target of $49, unchanged from prior coverage, according to the Investing.com article.

Technically, the 15-minute chart for Genmab indicates a bearish trend. The MACD indicator crossed below its signal line, and the KDJ indicator reached a point of convergence with the 20-day moving average, both occurring at 09:45 on October 20, 2025. This configuration suggests that the stock price has the potential to continue trending downwards, with a shift in momentum towards the downside .